KRRO — Korro Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703647 ·
Last close
$10.37
Market Cap
$149.56M
52W High
$15.55
52W Low
$9.12
ADV30
253,450
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -20,436,000 | -19,625,000 | 183,622,000 | 61,697,000 | 63,989,000 |
| Dec 2025 | 1,292,000 | — | -15,883,000 | -50,042,000 | 113,506,000 | 21,824,000 | 62,067,000 |
| Sep 2025 | 1,090,000 | — | -19,237,000 | -18,061,000 | 161,550,000 | 24,155,000 | 62,518,000 |
| Jun 2025 | 1,460,000 | — | -27,202,000 | -25,770,000 | 180,425,000 | 33,612,000 | 65,322,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-78,561,000
Investing CF
$43,993,000
Financing CF
$685,000
CapEx
$-518,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.41
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-383,846,000
Inventory
—
Receivables
$969,000
ST Investments
$53,332,000
EBIT TTM
$-87,342,000
Pretax Income TTM
$-116,623,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,842,000
EBITDA
$-79,323,000
Free Cash Flow
$-39,038,124
Enterprise Value
$78,477,064
Total Cash
$113,970,000
Total Debt
$42,885,000
Shares Out
14,422,571
Trailing EPS
$-11.68
Book Value
$8.29
ROE
-87.8%
ROA
-26.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,392,000 | -87,342,000 | -117,260,000 | 113,506,000 | 62,067,000 | — | -78,561,000 |
| Dec 2024 | 2,271,000 | -91,910,000 | -83,581,000 | 226,240,000 | 65,825,000 | — | -60,074,000 |
| Dec 2023 | 0 | -84,534,000 | -81,172,000 | 221,663,000 | 51,752,000 | — | -67,283,000 |
| Dec 2022 | 0 | -58,998,000 | -58,032,000 | 73,742,000 | 172,773,000 | — | -53,645,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NKTX | Nkarta, Inc. | $149.53M | $2.09 | — |
| OKUR | OnKure Therapeutics, Inc. | $154.31M | $3.82 | — |
| AARD | Aardvark Therapeutics, Inc. | $144.44M | $6.60 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $144.21M | $12.62 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $159.57M | $10.01 | — |
News headlines (Yahoo Finance, 1h cache)
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:05 · Yahoo
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-08 16:00 · Yahoo
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
2026-06-19 12:06 · Yahoo
One Korro Bio Insider Raised Stake By 19% In Previous Year
2026-06-11 11:38 · Yahoo
Korro to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-27 11:00 · Yahoo
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
2026-05-19 11:00 · Yahoo
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-15 20:05 · Yahoo
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 11:00 · Yahoo
Korro to Participate in Upcoming Investor Conferences
2026-05-05 20:05 · Yahoo
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
2026-04-28 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.